(PA-117) Optimisation of Patient-reported Outcome Measurement (PROMs) for Patients with Haematological Cancer Receiving CAR-T and Bispecific Antibodies: Multi-stakeholder Perspectives

Chimeric antigen receptor T-cell therapy (CAR-T) and T-cell engaging bispecific antibodies (BsAbs) are promising treatments for myeloma, leukaemia and lymphoma. However, they are associated with unique toxicities and high symptom burden. Standardised validated quality of life (QoL)/PROM tools are needed that capture the unique treatment related toxicity on QoL. 

The aim of this project was to explore and understand current experiences and challenges in PROM/QoL for BsAbs and CAR-T treatments in haematology and what can be done to further improve our understanding of patients’ experiences.

Methods:

We conducted 2 online workshops and interviews with patients, carers, patient organisations, expert physicians, researchers, industry, regulatory and payer representatives. Thematic analysis was conducted to identify key themes.

Results:

Thirty stakeholders participated in the 2 workshops, and we conducted 15 virtual interviews. Insights included that PROM selection for CAR-T and BsABs therapies is challenging, and no single PROM captures the domains most important to patients. Older general established QoL tools dominate despite their limitations. Capturing real-world patients’ specific treatment-related experiences and the broader impacts on emotional, social and mental health is missing.

Conclusions:

New sensitive PROMs tailored to CAR-T and BsAbs are required but harmonisation of QoL measures and follow-up timepoints is needed to optimise current PROM use in clinical trials and routine care in the interim. Continuing to capture patient-centred data on quality of life is invaluable to help build the evidence base whilst new tools are in development.